1. Piccart MJ, Awada A, Hamilton, A: Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. 35th ASCO Educational Book, pp526–539, 1999.
2. Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellmann S, Henderson IC, Kinne DW eds, Breast Diseases, 2nd ed, JB Lippincott Co, Philadelphia, pp604–665, 1991.
3. Stadtmauer EA, O’Neil A, Goldstein LJ, Crilley P, Mangan KF, Ingle JN, Lazarus HM, Erban J, Sickles C, Glick JH: Phase II randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotorexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia intergroup study (PBT-1). 35thProc Am Soc Clin Oncol 18:#1a, 1999.
4. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.Annal Oncol 7:807–813, 1996.
5. Meta-analysis group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectalcancer. J Clin Oncol 16:301–308, 1998.